Literature DB >> 33234942

68Ga-DOTANOC PET/CT With Lung Involvement in the Era of COVID-19 Pandemic.

Sarai Morón1, Eliana González, Julián Rojas.   

Abstract

ABSTRACT: Patient was a 55-year-old man with history of pancreas neuroendocrine tumor grade 2, Ki-67 index 10%. He was treated with surgical resection. 68Ga-DOTANOC PET/CT was performed as part of follow-up of known disease. The images showed opacities in both lungs' parenchyma with moderate uptake of radiotracer and mediastinal lymph nodes with high uptake suggestive of infection. Two weeks before a high-resolution CT was performed, these findings in the lungs were not present. The patient was asymptomatic and was referred to the emergency department for reverse transcriptase-polymerase chain reaction COVID-19 test, and the result was positive.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33234942      PMCID: PMC7780932          DOI: 10.1097/RLU.0000000000003473

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   10.782


A and B, High-resolution CT was performed in a 55-year-old man with pancreas neuroendocrine tumor grade 2 Ki-67 index 10% for follow-up of known disease 2 weeks before the 68Ga-DOTANOC PET/CT was performed. The findings were negative for infection or metastases (white arrows). C, Afterward, a 68Ga-DOTANOC PET/CT was performed. Maximum intensity projection image shows moderate and diffuse uptake in both lungs (black arrows) and high uptake in mediastinum (black arrowheads). No sites of metastatic disease were found. D and E, PET and PET/CT axial section demonstrates bilateral, multifocal, and peripheral ground-glass opacities with more involvement in both inferior lobes (SUVmax 4.3) and moderate somatostatin receptor expression in the lungs (black arrows) suggestive of COVID-19 infection. These findings were not present in the CT previously. F and G, PET and PET/CT axial section with right hilar, subcarinal, and Aortopulmonary window lymph nodes (white arrowhead), with high radiotracer uptake (SUVmax 5.5) suggestive of inflammatory process and COVID-19 infection. On January 30, 2020, the WHO Director-General Dr Tedros Adhanom Ghebreyesus declared the 2019-nCoV outbreak a public health emergency of international concern. By September 6, 2020, 7:00 pm GMT-5, there were 26,994,442 confirmed cases, 880,994 deaths, and 216 countries affected.[1] In Colombia, by September 6, 2020, 5:00 pm GMT-5, the confirmed cases are 666,521 with 21,412 deaths.[2] The nuclear medicine departments around the world have had a challenge in facing the pandemic. They did not discontinue their operation. The “COVID-19 Pandemic: Guidance for Nuclear Medicine Departments”[3] suggested some recommendations. One of these is the incidental COVID-19 finding in hybrid study that involves a CT of the chest. If COVID-19 findings are detected in the lungs, it must be reported immediately. The image acquisition of 68Ga-DOTA peptides PET/CT is from the head to the middle of the upper leg[4] and includes the chest. Therefore, there may be incidental detection in chest part in asymptomatic but infected cases undergoing scans for other indications.[5] Moreover, uptake in inflammatory processes is described in 68Ga-DOTA peptides because white blood cells including leukocytes and macrophages express somatostatin receptor 2,[6] and it should be considered in COVID-19 times. There are few cases reported of COVID-19 findings in PET/CT with radiotracers different from 18F-FDG. Scarlattei et al[7] reported 5 cases of unknown SARS-CoV-2 pneumonia detected by PET/CT with 18F-FDG, 18F-choline, and 68Ga-prostate-specific membrane antigen. Stasiak et al[8] reported 1 case with COVID-19 infection after 68Ga–prostate-specific membrane antigen-11 PET/CT imaging in a patient with prostate cancer. Moreover, Vicente and Castrejón[9] and Olivari et al[10] reported one case with incidental COVID-19 pneumonia on 18F-choline PET/CT for biochemical recurrence of prostate cancer and COVID-19 pneumonia increased choline uptake with 18F-choline PET/CT, respectively. However, none of these case reports are with 68Ga-DOTA peptides. This case demonstrates findings of COVID-19 in 68Ga-DOTANOC PET/CT in an asymptomatic patient with the infection confirmed by reverse transcriptase–polymerase chain reaction.
  9 in total

1.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

2.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.

Authors:  Michael S Hofman; W F Eddie Lau; Rodney J Hicks
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

3.  Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region.

Authors:  Domenico Albano; Francesco Bertagna; Mattia Bertoli; Giovanni Bosio; Silvia Lucchini; Federica Motta; Maria Beatrice Panarotto; Alessia Peli; Luca Camoni; Frank M Bengel; Raffaele Giubbini
Journal:  J Nucl Med       Date:  2020-04-01       Impact factor: 10.057

4.  COVID-19 pneumonia: increased choline uptake with 18F-choline PET/CT.

Authors:  Laura Olivari; Niccolò Riccardi; Paola Rodari; Andrea Angheben; Paolo Artioli; Matteo Salgarello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-04       Impact factor: 9.236

5.  Unknown SARS-CoV-2 pneumonia detected by PET/CT in patients with cancer.

Authors:  Maura Scarlattei; Giorgio Baldari; Mario Silva; Stefano Bola; Antonino Sammartano; Silvia Migliari; Tiziano Graziani; Carla Cidda; Nicola Sverzellati; Livia Ruffini
Journal:  Tumori       Date:  2020-06-22       Impact factor: 2.098

6.  Impact of Coronavirus disease (COVID-19) pandemic on health professionals.

Authors:  Bilal Ahmed Sethi; Ahsan Sethi; Sadaf Ali; Hira Shireen Aamir
Journal:  Pak J Med Sci       Date:  2020-05       Impact factor: 1.088

7.  Incidental COVID-19 Pneumonia on 18F-Fluorocholine PET/CT.

Authors:  Ana María García Vicente; Ángel Soriano Castrejón
Journal:  Clin Nucl Med       Date:  2020-08       Impact factor: 7.794

8.  Incidental finding of COVID-19 infection after [68Ga]Ga-PSMA-11 PET/CT imaging in a patient with prostate cancer.

Authors:  Camila Edith Stachera Stasiak; Fabrícius Rocha Cardoso; Sergio Altino de Almeida; Paulo Henrique Rosado-de-Castro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-24       Impact factor: 9.236

9.  COVID-19 pandemic: guidance for nuclear medicine departments.

Authors:  D Paez; G Gnanasegaran; S Fanti; J Bomanji; M Hacker; M Sathekge; H S Bom; J J Cerci; A Chiti; K Herrmann; A M Scott; J Czernin; N El-Haj; E Estrada; O Pellet; P Orellana; F Giammarile; M Abdel-Wahab
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.